Catalog No.S1002

ABT-737 Chemical Structure

Molecular Weight(MW): 813.43

ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.

Size Price Stock Quantity  
In DMSO USD 384 In stock
USD 120 In stock
USD 200 In stock
USD 570 In stock
USD 970 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 88 Publications

14 Customer Reviews

  • Cardiomyocytes transduced with or without Ad-Mst1 were treated with ABT-737 (0, 0.1, 1, 10 uM) for 12 hours. Representative immunoblots with antibodies to p62/SQSTM1, LC3 and GAPDH are shown.

    Nat Med 2013 19(11), 1478-88. ABT-737 purchased from Selleck.

    BCL-XL mediates human neutrophil survival. PMNs were preincubated with the BH3 mimetic ABT-737 (1–10 μM), then cultured in normoxia (gray bars) with or without GM-CSF (500 U/ml) or hypoxia (white bars)or 20 hours, and apoptosis was assessed by morphology (n = 4).



    J Clin Invest 2011 121, 1053-1063. ABT-737 purchased from Selleck.

  • Release of mitochondrial cytochrome c and loss of mitochondrial membrane potential after exposure to ABT-737 (100nM) for 2 hours were assessed by immunohistochemistry and staining with TMRE (red, top panels) and anti-CD41/FITC (green, top panels). Bar represents 5 um. Note that control cells display spreading on glass slides, whereas ABT-737-treated cells do not.

    Blood 2011 17(26), 7145-54. ABT-737 purchased from Selleck.

    Platelets were incubated in HBS with or without ABT-737 (100nM) for 2 hours before analysis by immunohistochemistry and confocal microscopy. Actin was stained using phalloidin/Alexa-488 (green), and tubulin was stained using anti-tubulin/phycoerythrin (red). Bar represents 5 uM.

    Blood 2011 17(26), 7145-54. ABT-737 purchased from Selleck.

  • Analysis of SW480 and SW620 cell sensitivity to the BH3-mimetic ABT-737. (a, b) Percentage of apoptosis in adherent or suspended SW480 (a) or SW620 (b) cells cultured in the presence (ABT-737) or absence (ctrl) of ABT-737 (1 uM).

    Cell death dis 2013 4, e801. ABT-737 purchased from Selleck.

    Bcl-XL/Bcl-2 inhibitor ABT-737 aggravates the proapoptotic effects of IL-1IFN-. INS-1E cells were transfected with single or smart Pool PUMA siRNAs and exposed to ABT-737 for 24 h. At this time point, cell death was measured by HO/PI, n  3. *, p  0.05; **, p  0.01.



    J Biol Chem 2010 285, 19919-19920. ABT-737 purchased from Selleck.

  • Effect of ABT-737 on the cell viability of CCRF-CEM cells by treatments of AY4 (10 μg/ml), TRAIL (0.5 μg/ml), SAHA (1 μM),VPA (1 mM), or ABT-737 (10 μM) alone or in combination for 24 h prior to MTT assay.



    Apoptosis 2010 15, 1256-1269. ABT-737 purchased from Selleck.

    Upper panel ABT-737 inhibits TFK-1 and EGI-1 cell growth.Cells were exposed to ABT-737 at a concentration ranging from 1 to 50 lM. Following 72 h of incubation, growth inhibition was analyzed by crystal violet assay. Dose–effect plot of ABT-737 treatment is presented.



    Cancer Chemoth Pharm 2011 67, 557-567. ABT-737 purchased from Selleck.

  • Lower panel detection of PARP-1, cleaved caspase-9 and caspase-3, BCL-2 and MCL-1 in TFK-1 and EGI-1 cells after 72 h of ABT-737 treatment (1, 3, 10, 25,50 μM). Cell lysates were analyzed on Western blotting.



    Cancer Chemoth Pharm 2011 67, 557-567. ABT-737 purchased from Selleck.

    3 μM ABT737 inhibited growth and viability of TF-1 cells and potentiated proapoptotic effects of 1 μM BIO after 72 hours treatment. TF-1 cells treated with both drugs exhibited more apoptotic cells compared to those treated with each single drug. ABT737 abrogated the protection from BIO-induced apoptosis provided by MS5 coculture.



    Exp Hematol 2010 38, 908-921. ABT-737 purchased from Selleck.

  • GSIXII synergized with ABT-737 to trigger apoptosis in breast cancer cells . Breast cancer cell lines were incubate d for 48 hours with 10μM GSIXII or DMSO (Ct) in combination or not with ABT-737, 1 μM. Then apoptosis was evaluated with Apo2.7 or Annexin-V staining and flow-cytometry analysis. Represented data are the means of positive cells ± SEM, from three independent experiments.(A) Suboptimal concentrations of GSIXII (5 μM) and 1 μM ABT-737 were used alone or in combination in MFU assay in MCF7 and BT549 cell lines. Results were obtained from three independent experiments and compared with mock-treated condition. (B) The 20 μM SAHM1 was used alone or in combination in MFU assay in MCF7 and BT549 cell lines. Results were obtained from three independent experiments and compared with the mock-treated condition.

    Biochem Biophys Res Commun 2013 408, 344-9. ABT-737 purchased from Selleck.

    Apoptosis induced by BCL2-inhibitors in P-glycoprotein expressing cells. MDCKII wild type or MDR1 cells were exposed to different concentrations of ABT-737 (C) or ABT-263 (D) for 24 h before apoptosis was assessed by flow cytometry using externalization of phosphatidylserine.

    Biochem Biophys Res Commun 2012 408, 344-9. ABT-737 purchased from Selleck.

  • MEF wt and MEF Mcl-1 ko mice activating active caspase-3 using 1um ABT for 24h



    Dr. Arnim Weber of Medizinische Mikrobiologie und Hygiene Universitatsklinikum Freiburg. ABT-737 purchased from Selleck.

    MDB-MA-231 cells were exposed to 30 um cisplatin in the absence or in thepresence of 100nm ABT-737.The cell were stained with Hoechst 33342,MitoTracker Red and Yo-pro-1.



    Dr. Zhang of Tianjin Medical University. ABT-737 purchased from Selleck.

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Click to view more


2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.
Features First-generation inhibitor of anti-apoptotic Bcl-2 proteins.
Bcl-2 [1]
(Cell-free assay)
Bcl-xL [1]
(Cell-free assay)
Bcl-w [1]
(Cell-free assay)
Bcl-B [1]
(Cell-free assay)
Bfl-1 [1]
(Cell-free assay)
30.3 nM(EC50) 78.7 nM(EC50) 197.8 nM(EC50) 1.82 μM(EC50) >10 μM(EC50)
In vitro

ABT-737 shows low activity to Bcl-B and no effects to Mcl-1 and BFL-1. ABT-737 is sensitive to HL60, KG1 and NB4 cells with IC50 of 50 nM, 80 nM and 80 nM, respectively. ABT-737 induces apoptosis in HL60 cells, which due to decreased Bcl-2/Bax heterodimerization and has no effect on cell cycle distribution. ABT-737 also induces cytochrome c release from purified mitochondria and promotes conformational changes in Bax that are associated with apoptosis. [1] Resistant cells (Hela and MCF-7) can be sensitized to ABT-737 by approaches that down-regulate, destabilize, or inactivate Mcl-1. ABT-737 also causes Bax/BAK-dependent cytochrome c release only when Mcl-1 has been neutralized. [2] ABT-737 displaces Bim from Bcl2's BH3-binding pocket, allowing Bim to activate Bax, induce mitochondrial permeabilization, and rapidly commit the primary chronic lymphocytic leukemia (CLL) cells to death. [3] Knockdown of Mcl-1 with siRNA sensitizes two resistant SCLC cell lines H196 and DMS114 to ABT-737 by enhancing the induction of apoptosis. Likewise, up-regulation of Noxa sensitizes H196 cells to ABT-737. ABT-737 inhibits proliferation and induces apoptosis in many SCLC cell lines including NCI-H889, NCI-H1963, NCI-H1417, NCI-H146 and etc. Bcl-2 and Noxa may contribute mechanistically to the cellular response to ABT-737 in NCI-H146 cells. [4] A recent study shows that ABT-737 significantly induces apoptosis in HTLV-1 infected T-cell lines as well as in fresh ATLL cells. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
OCI-Ly1  Mlm3R4VtdCCYaXHibYxqfHliQYPzZZk> NFjTTI4zPTBibl5CpC=> MmL2O|IhcA>? NFLCZ4FFVVOR M1HJ[oNifXOnZDC5O{UhdG:|czDv[kB3cWGkaXzpeJkhcW5iY3XscJMhfHKjboPm[YN1\WRid3n0bEBDS0x4IIPpVm5C MoWzNlY3PTd{OEi=
KG1a MV3D[YxtKF[rYXLpcIl1gSCDc4PhfS=> MmrUNE0yOCEQvF2= MXKyOEBp NIfiOFNFVVOR NUHOTJNNUUN3ME23MlY5KM7:TTyg[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MU[yOlU2OjdzMh?=
Kasumi-1 NXW2WmhJS2WubDDWbYFjcWyrdImgRZN{[Xl? NGfNZmMxNTFyIN88US=> Mn72NlQhcA>? NFX1ZYxFVVOR NIrnRmpKSzVyPUSuPFch|ryPLDDk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? Mnq4NlY2PTJ5MUK=
KG1a Ml;zRZBweHSxc3nzJGF{e2G7 M{Xr[lAuOTBizszN MoXwNlQhcA>? M3yye2ROW09? MXfpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MV:yOlU2OjdzMh?=
Kasumi-1 NI\r[nZCeG:ydH;zbZMhSXO|YYm= NF3rW2cxNTFyIN88US=> NX;6do1FOjRiaB?= M{H1T2ROW09? M2rFUYlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MoHhNlY2PTJ5MUK=
MC-3  M4XOfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\QOU8yOC9{MDFOwG0> MX2yOEBp NIX3XIJFVVOR M124eolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NXz3bph5OjZ2NEe2NVU>
HN22  NVuxUIpkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TUe|IvPS95LkWvNlIvPSEQvF2= MY[yOEBp MmjlSG1UVw>? MnO0bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MV[yOlQ1PzZzNR?=
MC-3  M3XUcmFxd3C2b4Ppd{BCe3OjeR?= MUS1M|ExNzJyIN88US=> M3jFd|I1KGh? NYLhXHNUTE2VTx?= NETxV41qdmS3Y3XzJINie3Cjc3WtcYVlcWG2ZXSgZZBweHSxc3nz NXj1[GZbOjZ2NEe2NVU>
HN22  NWjyWGlESXCxcITvd4l{KEG|c3H5 M4S5WlIvPS95LkWvNlIvPSEQvF2= NH\mcI8zPCCq M4\jTWROW09? NF3UWI1qdmS3Y3XzJINie3Cjc3WtcYVlcWG2ZXSgZZBweHSxc3nz NV\2TGg6OjZ2NEe2NVU>
MOLT-4 NGK2e2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVWxNE02ODByIH7N MkW3O|IhcA>? MYLEUXNQ M{[wV2lEPTB;MD6xPVgh|ryP MViyOlM6OjN|Mh?=
RS4;11 MoHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnpNVAuPTByMDDuUS=> MWm3NkBp NUPTW2gzTE2VTx?= MmHvTWM2OD1yLkCwNkDPxE1? NF7DZXUzPjN7MkOzNi=>
MOLT-4 MonmRZBweHSxc3nzJGF{e2G7 MVKxNE0yODByIH7N M2[wZlI1KGh? NYHKV4Z{TE2VTx?= M2\jXINifXOnczD0bIUh[2ynYY\h[4Uhd2ZiQnPsMVIh[W6mIITo[UBld3ewcnXneYxifGmxbjDv[kBD[2xveFygZY5lKE2lbD2x NYXwRoR{OjZ|OUKzN|I>
CEM S NF7acIpCeG:ydH;zbZMhSXO|YYm= Mlm0NVAuOTByMDDuUS=> MoDONlQhcA>? NWOyc3hkTE2VTx?= M1OyWoNifXOnczD0bIUh[2ynYY\h[4Uhd2ZiQnPsMVIh[W6mIITo[UBld3ewcnXneYxifGmxbjDv[kBD[2xveFygZY5lKE2lbD2x MV2yOlM6OjN|Mh?=
JURKAT NGC3NndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPHc5BJOTByLUGwNFAhdk1? Mle2OFghcA>? NVz4OXlITE2VTx?= MkC1TWM2OD17NUZCtVkvOyCwTR?= NWfzV2xHOjZzN{KyOlk>
WM-115 NGPjT4tE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NFiydoQyODEEoH7N MYi3NkBp M2rEWoVvcGGwY3XzJIN2emO3bXnuMYlv\HWlZXSgZY51cS2|dYL2bZZidMLi NGXSeXkzPjFzNke3Oi=>
B16 M3fjNWNmdGxiVnnhZoltcXS7IFHzd4F6 M37sc|ExOMLibl2= MnzZO|IhcA>? NUPVbWkz\W6qYX7j[ZMh[3W{Y4XtbY4ucW6mdXPl[EBidnSrLYP1dpZqfmGuwrC= NG\4XIIzPjFzNke3Oi=>
HL-60  MnnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnLO|IhcA>? M4XsSmlEPTEEoE2gNVAvPyCwTR?= NHHH[W4zPjB2NU[wPS=>
MOLM-13  MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYO0fZd5PzJiaB?= M16wSWlEPTEEoE2gNlcvQSCwTR?= NX;4U4VGOjZyNEW2NFk>
BCWM.1 Mn25RZBweHSxc3nzJGF{e2G7 MV[wMVEvPiEQvF2= MVmyOEBp MYHpcoR2[2W|IHPlcIwh[XCxcITvd4l{ MlftNlU5QTN{OUC=
MWCL-1 M1HuRWFxd3C2b4Ppd{BCe3OjeR?= M2fNW|AuOS54IN88US=> NVTUbG85OjRiaB?= M2jZcolv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MX6yOVg6OzJ7MB?=
MM.1s MWPBdI9xfG:|aYOgRZN{[Xl? MlnzNE0yNjZizszN NUf6NFJ1OjRiaB?= NUXCOIU6cW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MXuyOVg6OzJ7MB?=
HCT116 NWnGTHg4TnWwY4Tpc44hSXO|YYm= NY\wdopWOy9zMDFOwG0> MVGxNuKhcMLi NH7EdpVFVVOR NEXHeWpqdmS3Y3XzJIEh\G:|ZT3k[ZBmdmSnboSgbY5kemWjc3WgbY4hVEN|Qj3JTUBkd264ZYLzbY9vKGGwZDDTVXNVVTFiZHXndoFl[XSrb36= MXyyOVcyPTB{OB?=
HCT116 BAX BAK1 DKO Ml;2SpVv[3Srb36gRZN{[Xl? NUHrcoY1Oy9zMDFOwG0> MoXKNVLDqGkEoB?= MkTqSG1UVw>? MVLpcoR2[2W|IHGg[I9{\S2mZYDlcoRmdnRiaX7jdoVie2ViaX6gUGM{Si2LSTDjc453\XK|aX;uJIFv\CCVUWPUUVEh\GWpcnHkZZRqd25? MXKyOVcyPTB{OB?=
HCT116 MX3GeY5kfGmxbjDBd5NigQ>? Mn7CNVAh|ryP NX\zeop1OTMEoHlCpC=> M3v4RWROW09? M2P0colv[3KnYYPld{BITlBvTFOzRkBxfW6ldHG= NGTneIczPTdzNUCyPC=>
HCT116 BAX BAK1 DKO M2\2XGF2fG:yaHHnfUBCe3OjeR?= NW[4Omd2OTBizszN M4T4WlEzyqCqwrC= M2TOWGROW09? M1nRcolv\HWlZYOgZUBkd22ybHX0[UBifXSxcHjh[4lkKHKnc4DvcpNm MYSyOVcyPTB{OB?=
U937 NWr5eG9KSXCxcITvd4l{KEG|c3H5 MnHENE4yOjVvMjFOwG0> M1;MU|I1KGh? NVmyVlQy\W6qYX7j[ZMhTEiDL2itNVEucW6mdXPl[EBieG:ydH;zbZM> MUOyOVcyPDB{NB?=
HL-60 AAA-Bcl-2 NWLlUph6SXCxcITvd4l{KEG|c3H5 MkD4NE02KM7:TR?= MnfYOFghcA>? M3nrfGlEPTB;MD64O{DPxG4xvJzpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MXmyOVcyOTR4MB?=
HL-60 EEE-Bcl-2 NXfJUYhuSXCxcITvd4l{KEG|c3H5 M{TBfVAuPSEQvF2= MYK0PEBp MlftTWM2OD13IN88cg+9lCCrbnT1Z4V{KGOnbHygZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MUCyOVcyOTR4MB?=
U87 NUfySpA6TnWwY4Tpc44hSXO|YYm= MX[1NEDPxE1? NVvIPIRbOjRiaB?= NV7UUIs4emWmdXPld{B1cGVibWLORUBmgHC{ZYPzbY9vKGyndnXsd{Bw\iCPTWCtNkwhVU2SLUG0JIFv\CCEY3ytNi=> NWm4fWlEOjV4Nke2OlM>
K562 M1;LO2NmdGxiVnnhZoltcXS7IFHzd4F6 MXexMVExKM7:TR?= MmXvOFghcA>? NULmcIdITE2VTx?= NUfRSm1HUUN3ME2yOk44KM7:TR?= NFLqU2szPTV7NkW2NS=>
K562/Mcl -1-IRESBim NWXK[IJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTlwMzFOwG0> MXeyOVU{PTlyMB?=
K562/Bcl- 2-IRESBim NHHoV5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWG4PY4zUUN3ME2wMlM2KM7:TR?= Mo\LNlU2OzV7MEC=
Jurkat MkDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTBwNk[g{txO MX[yOVU{PTlyMB?=
JurkatΔBak NUP5O|VqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHkdpVKSzVyPkWwJO69VQ>? MWqyOVU{PTlyMB?=
HL60/VCR M1P1OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRjFyMDFOwG0> M1zkSlI2PTN3OUCw
Kasumi-1 NUPvZ|ZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPOfXByUUN3ME2wMlAyKM7:TR?= M4qxW|I2PTN3OUCw
Kasumi-1/ABT NWDzO5hzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnKOlVKSzVyPUCuOVEh|ryP NEHWcYozPTV|NUmwNC=>
THP-1 MnLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTFwMkeg{txO NFjpT5czPTV|NUmwNC=>
U937 NHnPfGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTVwMkmg{txO M1XJSlI2PTN3OUCw
C1498 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTZwMUOg{txO MmHpNlU2OzV7MEC=
RPMI 8226 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfOO|NKSzVyPUCuNlUh|ryP MX6yOVU{PTlyMB?=
NCI-H929 NHfmb4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPMTWM2OD1zNT6yNUDPxE1? Mm\qNlU2OzV7MEC=
U266 NYfLPJMxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml[1TWM2OD1yLk[4JO69VQ>? M13pblI2PTN3OUCw
MCF-7 M1zaUGNmdGxiVnnhZoltcXS7IFHzd4F6 NEjORVI2KM7:TR?= NF3L[Jo1QCCq MonjSG1UVw>? M{DUc4VvcGGwY3XzJJRp\SC|ZX7zbZRqfmm2eTD0c{BweiC{YXTpZZRqd25? MV2yOVQxQTF{NB?=
MCF-7 MnfpRZBweHSxc3nzJGF{e2G7 M4jRVFUh|ryP MXK0M|I1NzR6IHi= M{LB[2ROW09? MUjpcoNz\WG|ZYOgeIhmKGOuZXH2[YQhWEGUUB?= MlnUNlU1ODlzMkS=
MCF-7 NEX2dGRHfW6ldHnvckBCe3OjeR?= MVe1JO69VQ>? NF\ZNoczPCCq MWrEUXNQ MUflcohidmOnczD0bIVt\X[nbDDv[kBO[2xvMTDlfJBz\XO|aX;uxsA> Mlz6NlU1ODlzMkS=
MDA-MB 231  M3e2bWZ2dmO2aX;uJGF{e2G7 M2XFflUh|ryP NGHmOnEzPCCq M1XIfmROW09? M{HFc4VvcGGwY3XzJJRp\WyndnXsJI9nKE2lbD2xJIV5eHKnc4Ppc47DqA>? MWOyOVQxQTF{NB?=
ZR-75-1  MXXGeY5kfGmxbjDBd5NigQ>? NH7Gfo82KM7:TR?= NH3R[nEzPCCq M{HPe2ROW09? NIPWSG9mdmijbnPld{B1cGWuZY\lcEBw\iCPY3ytNUBmgHC{ZYPzbY9vyqB? M2[0Z|I2PDB7MUK0
A549 NUiyVZE4S2WubDDWbYFjcWyrdImgRZN{[Xl? M2WwNFAuOjBizszN NUTy[3RJPzJiaB?= NG\HV3BFVVOR MlSy[IVkemWjc3XzJJRp\SClZXzsJJN2en[rdnHsJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJINwdWKrbnXkJJdqfGhiYYPwbZJqdg>? MUOyOVM5QDd4Mh?=
H1299 M2rD[2NmdGxiVnnhZoltcXS7IFHzd4F6 Mn73NE0zOCEQvF2= MnLNO|IhcA>? NXWySFRlTE2VTx?= NXi3T|l7\GWlcnXhd4V{KHSqZTDj[YxtKHO3co\peoFtKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzKGOxbXLpcoVlKHerdHigZZNxcXKrbh?= Mn34NlU{QDh5NkK=
HO-8910 NFfw[HlE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NX25boJrOC1{MDFOwG0> NV\TcnZ[PzJiaB?= M3nvbmROW09? M3vzbIRm[3KnYYPld{B1cGViY3XscEB{fXK4aY\hcEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldkBkd22kaX7l[EB4cXSqIHHzdIlzcW5? M4jpSVI2Ozh6N{[y
HT-29 NF7GOVhE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NH7C[o8xNTJyIN88US=> M4CwU|czKGh? NGrhfY9FVVOR NI[2eVdl\WO{ZXHz[ZMhfGinIHPlcIwhe3W{dnn2ZYwhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZIh[2:vYnnu[YQhf2m2aDDhd5Bqemmw MYmyOVM5QDd4Mh?=
HCT-116 M1r2eGNmdGxiVnnhZoltcXS7IFHzd4F6 NHHiPXAxNTJyIN88US=> MXu3NkBp Ml\ySG1UVw>? NISyVJZl\WO{ZXHz[ZMhfGinIHPlcIwhe3W{dnn2ZYwhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZIh[2:vYnnu[YQhf2m2aDDhd5Bqemmw NGnvVJIzPTN6OEe2Ni=>
A549 MYnBdI9xfG:|aYOgRZN{[Xl? NHvCU48zOCEQvF2= NIizSVc1QCCq NFPTZVZFVVOR MoXtbY5lfWOnczDhdI9xfG:|aYOgd4lodmmoaXPhcpRtgSClb33ibY5m\CC5aYToJIF{eGm{aX6= M2C2NFI2Ozh6N{[y
H1299 MYDBdI9xfG:|aYOgRZN{[Xl? MkjWNlAh|ryP NGrQOVk1QCCq M3PlPWROW09? Ml7BbY5lfWOnczDhdI9xfG:|aYOgd4lodmmoaXPhcpRtgSClb33ibY5m\CC5aYToJIF{eGm{aX6= NYi0NYNqOjV|OEi3OlI>
Sc-1 MUXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MlqzNE4xODBzLUGg{txO MonVPVYhcA>? MVzk[YNz\WG|ZYOgeIhmKGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MmjvNlU{PzN3MEi=
OcI-LY18 M2TlO2NmdGxiVnnhZoltcXS7IFHzd4F6 NIfwRYoxNjByMEGtNUDPxE1? MW[5OkBp MmnO[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NIHUepczPTN5M{WwPC=>
RL  NH\wXZFE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MlX1NE4xODBzLUGg{txO MYm5OkBp NVLo[G9o\GWlcnXhd4V{KHSqZTDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M173UlI2Ozd|NUC4
Caco-2 MnXPR4VtdCCYaXHibYxqfHliQYPzZZk> M4PxSFAuOTBizszN NWjRU2tPOjUkgJnoxsA> MUXEUXNQ NH3yeo9KSzVyPUG5MlfjiIoEtV2= NIfU[3AzPTNyNEO4Ny=>
LS411N MmWwR4VtdCCYaXHibYxqfHliQYPzZZk> MlzYNE0yOCEQvF2= MnPuNlTjiImqwrC= Mn7vSG1UVw>? NH;sWWhKSzVyPUGxMlQ46oDLwsXN NX;Td|JxOjV|MESzPFM>
SW620 NGHNe4tE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MUewMVExKM7:TR?= MmT4NlTjiImqwrC= MYrEUXNQ M4PJcWlEPTB;MUKuNlTjiIoEtV2= M3;lU|I2OzB2M{iz
HCT116 NHn0U3VE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NHjkW2QxNTFyIN88US=> M1HmflI16oDLaNMg NUPZcWdKTE2VTx?= NYXxV|lSUUN3ME2yNE41QeLCidM1US=> M4\oflI2OzB2M{iz
HaCaT M4GwVWNmdGxiVnnhZoltcXS7IFHzd4F6 MXWwMlEwOS9zMDFOwG0> M1\2OFI1KGh? M1i3VGROW09? NFr6VZNl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MVmyOVIyODd7NR?=
A5-RT3 NX35cm5{S2WubDDWbYFjcWyrdImgRZN{[Xl? MnuzNE4yNzFxMUCg{txO NVGzSnppOjRiaB?= M3nrPWROW09? NUiwOJR1\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MnTvNlUzOTB5OUW=
HaCaT NUHPUlVoTnWwY4Tpc44hSXO|YYm= MmL5NVDjiIoQvF2= M1HpRVI1NzR6IHi= NUDReZV{TE2VTx?= M{Pjbolv\HWlZYOgUW1RKGGwZDDEUmEh\nKjZ33lcpRifGmxbh?= M3nyd|I2OjFyN{m1
A5-RT3 MoDQSpVv[3Srb36gRZN{[Xl? M{XCe|Ex6oDLzszN MYqyOE81QCCq M3\i[mROW09? MUTpcoR2[2W|IF3NVEBidmRiRF7BJIZz[WevZX70ZZRqd25? MWKyOVIyODd7NR?=
A5-RT3 MkGySpVv[3Srb36gRZN{[Xl? M4DRUVUh|ryP MmrIOkBp NUDX[5pRTE2VTx?= NUnROJY2cW6mdXPld{B1cGVicnXs[YF{\SCxZjDtbZRw[2ixbnTybYFtKHC{b4TlbY5{KGGwZDDy[YR2[2W|IHPsc45w\2WwaXOgd5Vzfmm4YXygbY4h[SClYYPwZZNmNWmwZHXw[Y5l\W62IH3hco5meg>? NYXlbY02OjV{MUC3PVU>
U266 NHz5d3RHfW6ldHnvckBCe3OjeR?= M1XHfFUxOC95NUCgcm0> MYiyOE81QCCq NEewfI5FVVOR Ml7L[I94dnKnZ4XsZZRmeyCEaX2sJJBzcW6laYDhcIx6KHSqZTDFUEBqe2:ob4Lt NVrIPZlvOjV{MEi4PFg>
RPMI8226 NXu4fXlqTnWwY4Tpc44hSXO|YYm= M1S1OFUxOC95NUCgcm0> MUKyOE81QCCq MkHRSG1UVw>? MlrX[I94dnKnZ4XsZZRmeyCEaX2sJJBzcW6laYDhcIx6KHSqZTDFUEBqe2:ob4Lt M3z4UFI2OjB6OEi4
MM.1S NFHzOmdHfW6ldHnvckBCe3OjeR?= MlvnOVAxNzd3MDDuUS=> NHrUNoUzPC92ODDo M1vLWWROW09? NWjRR3pz\G:5boLl[5Vt[XSnczDCbY0tKHC{aX7jbZBidGy7IITo[UBGVCCrc3;mc5Ju MnLNNlUzODh6OEi=
LS174T MlPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH2zfHcxNjMkgKO2NEDPxE1? M3TWelczKGh? MUfEUXNQ NHqwRZZKSzVyPUG4MlMh|ryP NIX0WJozPTJyOEi4Ni=>
HT29 M{X0dmFxd3C2b4Ppd{BCe3OjeR?= M1PKNlEwPS9zMDFOwG0> NGnx[JU1QCCq NIn4VGVk[XW|ZYOgZ4VtdCCmZXH0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NGW2dpUzPTF7MkG4PC=>
SW480 MnzDRZBweHSxc3nzJGF{e2G7 NGnCVm4yNzVxMUCg{txO NFnucmE1QCCq M3S2NINifXOnczDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MljzNlUyQTJzOEi=
Colo205 NF\qdo9CeG:ydH;zbZMhSXO|YYm= MWOxM|UwOTBizszN NWi3fWp1PDhiaB?= M3fNe4NifXOnczDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MorBNlUyQTJzOEi=
Caco2 Mm\2RZBweHSxc3nzJGF{e2G7 MnqyNU82NzFyIN88US=> MX20PEBp NYD0cXpv[2G3c3XzJINmdGxiZHXheIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NWPTPYV3OjVzOUKxPFg>
PCI-13 M3r1fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXJO|IhcA>? NGL5OJhFVVOR Mli2S2k2OD1zNTFCtUAyNjhizszN M1nr[lI2OTN7M{i3
PCI-15B MnP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFq2Vmw4OiCq MVzEUXNQ NX3vcmFmT0l3ME2xNUDDuSB2LkWg{txO NYG3SWR3OjVzM{mzPFc>
UM-SCC22B M1TFT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TlVlczKGh? NIDwZ3pFVVOR MmjSS2k2OD1zOTFCtUAzNjlizszN M1uxdFI2OTN7M{i3
UM-SCC47 NWDSPHliT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXFeWlYPzJiaB?= M3\yZWROW09? NVn1NWtJT0l3ME2xPUDDuSBzMj6zJO69VQ>? MnPBNlUyOzl|OEe=
93-VU-147T MoLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYO1dplDPzJiaB?= M1\xc2ROW09? M2TsdmdKPTB;ND6zJOKyKDNwNTFOwG0> M{Xj[VI2OTN7M{i3
UD-SCC2 MnuyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIO5XpQ4OiCq M3vOeGROW09? MnnCS2k2OD1{ODFCtUAzNjlizszN M4THTFI2OTN7M{i3
UPCI:SCC90 NFn0fWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7kTHk4OiCq NFT0c4ZFVVOR NY[5eZk3T0l3ME22MlYhyrFiMT61JO69VQ>? NEHIXJczPTF|OUO4Oy=>
RPMI-8226  NXjscWtES2WubDDWbYFjcWyrdImgRZN{[Xl? MVexNlUwOjVyL{WwNEBvVQ>? NIDH[4Q1QGkEoB?= MXPEUXNQ MkX5[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NF65dHgzPTByOEKwNi=>
RPMI-8226  NWT1[2VUSXCxcITvd4l{KEG|c3H5 MYmxNlUwOjVyL{WwNEBvVQ>? MkLLOFhpyqB? Ml3TSG1UVw>? MX3pcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz Ml;6NlUxODh{MEK=
OPM-2  NWjveYZOSXCxcITvd4l{KEG|c3H5 MonnNVI2NzJ3MD:1NFAhdk1? M{PRW|Q5cMLi MoDISG1UVw>? NUnJPWZ[cW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NIjsUW4zPTByOEKwNi=>
COG-LL-319 MkTMSpVv[3Srb36gRZN{[Xl? MVKxNFAhdk1? NEXTWGMyNzNxNjDo MoDTSG1UVw>? Mn3WbY5lfWOnczDjZZNx[XOnLXTldIVv\GWwdDDNZ4wuOSClbHXheoFo\Q>? MXqyOFk2OTR5Mh?=
RS4;11 NGDXRpFHfW6ldHnvckBCe3OjeR?= MnjpNVAxKG6P NGDhZnIyNzNxNjDo NGmwNpJFVVOR Mn;xbY5lfWOnczDjZZNx[XOnLXTldIVv\GWwdDDNZ4wuOSClbHXheoFo\Q>? MnzvNlQ6PTF2N{K=

... Click to View More Cell Line Experimental Data

In vivo In aggressive leukemia model, ABT-737 suppresses the leukemia burden by 53% at the 30 mg/kg, with significantly extended survival of mice. ABT-737 does not induce significantly abnormalities in blood cell counts or serum chemistries. [1] ABT-737 prolongs the survival of recipient mice transplanted with Bcl-2-transduced tumors. [2] ABT-737 shows great antitumor activity in an ATLL mouse model at a dose of 100 mg/kg. [5]


Kinase Assay:


+ Expand

Fluorescence polarization assays:

Binding affinity of GST-Bcl-2 family proteins to the FITC-conjugated BH3 domain of Bim (FITC-Ahx-DMRPEIWIAQELRRIGDEFNAYYAR) is determined. Briefly, 100 nM of GST-Bcl-2 family fusion proteins are incubated with serial dilutions of ABT-737 in PBS for 2 min. Then, 20 nM of FITC-Bim BH3 peptide (FITC-Ahx-DMRPEIWIAQELRRIGDEFNAYYAR) is added. Fluorescence polarization is measured using an Analyst TM AD Assay Detection System after 10 min using the 96-well black plate. Then IC50 are determined.
Cell Research:


+ Expand
  • Cell lines: SCLC cell lines NCI-H889, NCI-H1963, NCI-H1417, NCI-H146, NCI-187, DMS79, NCI-1048, NCI-H82, NCI-H196, H69AR, and DMS114
  • Concentrations: 0.001-10 μM
  • Incubation Time: 48 hours
  • Method:

    SCLC cells are treated for 48 hours in 96-well tissue culture plates in a total volume of 100 μL tissue culture medium supplemented with 10% human serum. Viable cells are determined using the MTS assay.

    (Only for Reference)
Animal Research:


+ Expand
  • Animal Models: Scid mice injected with Luc-expressing FD/ΔRaf-1:ER cells
  • Formulation: 1 g/mL stock solution of ABT-737 in DMSO is added to a mixture of 30% propylene glycol, 5% Tween 80, 65% D5W (5% dextrose in water) (pH 4−5; final concentration of DMSO ≤ 1%)
  • Dosages: 20 and 30 mg/kg
  • Administration: For intraperitoneal (i.p.) every day
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (122.93 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 30% Propylene glycol, 5% Tween 80, 65% D5W 30mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 813.43


CAS No. 852808-04-9
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products

Tags: buy ABT-737 | ABT-737 supplier | purchase ABT-737 | ABT-737 cost | ABT-737 manufacturer | order ABT-737 | ABT-737 distributor
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID